NCT00941577View on ClinicalTrials.gov

Study Evaluating the Effects of AIR645 on Allergen-Induced Airway Responses in Subjects With Mild Atopic Asthma

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

October 31, 2009

Primary Completion Date

May 31, 2010

Study Completion Date

June 30, 2010

Conditions
Asthma
Interventions
DRUG

AIR645

AIR645 (blinded) by nebulization, range of doses, maximum of one dose per day, maximum of 6 doses in 22 days.

DRUG

Physiologic saline solution

Placebo (blinded) by nebulization, range of doses, maximum of one dose per day, maximum of 6 doses in 22 days.

Trial Locations (3)

Unknown

Hamilton

Laval

Saskatoon

Sponsors
All Listed Sponsors
lead

Altair Therapeutics, Inc.

INDUSTRY

NCT00941577 - Study Evaluating the Effects of AIR645 on Allergen-Induced Airway Responses in Subjects With Mild Atopic Asthma | Biotech Hunter | Biotech Hunter